Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Lingjærde OC[au]:

Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nik-Zainal S et al. Nature. (2016)

Breast Cancer Molecular Stratification: From Intrinsic Subtypes to Integrative Clusters. Russnes HG et al. Am J Pathol. (2017)

Neutral tumor evolution? Tarabichi M et al. Nat Genet. (2018)

Search results

Items: 1 to 50 of 83

1.

Deep Profiling of Genetic Aberrations and Clonal Evolution in Follicular Lymphoma.

Bai B, Vodák D, Nakken S, Wise JF, Blaker YN, Lingjærde OC, Brodtkorb M, Hilden V, Trøen G, Lorenz S, Lawrence MS, Myklebost O, Meza-Zepeda L, Beiske K, Hovig E, Smeland EB, Holte H, Myklebust JH.

Blood. 2019 Nov 13;134(Supplement_1):20. doi: 10.1182/blood-2019-128403.

PMID:
31723999
2.

PathTracer: High-sensitivity detection of differential pathway activity in tumours.

Nygård S, Lingjærde OC, Caldas C, Hovig E, Børresen-Dale AL, Helland Å, Haakensen VD.

Sci Rep. 2019 Nov 8;9(1):16332. doi: 10.1038/s41598-019-52529-3.

3.

miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer.

Lindholm EM, Ragle Aure M, Haugen MH, Kleivi Sahlberg K, Kristensen VN, Nebdal D, Børresen-Dale AL, Lingjaerde OC, Engebraaten O.

Mol Oncol. 2019 Oct;13(10):2278-2296. doi: 10.1002/1878-0261.12561. Epub 2019 Aug 28.

4.

Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy.

Hamfjord J, Guren TK, Dajani O, Johansen JS, Glimelius B, Sorbye H, Pfeiffer P, Lingjærde OC, Tveit KM, Kure EH, Pallisgaard N, Spindler KG.

Ann Oncol. 2019 Jul 1;30(7):1088-1095. doi: 10.1093/annonc/mdz139.

PMID:
31046124
5.

Breast cancer quantitative proteome and proteogenomic landscape.

Johansson HJ, Socciarelli F, Vacanti NM, Haugen MH, Zhu Y, Siavelis I, Fernandez-Woodbridge A, Aure MR, Sennblad B, Vesterlund M, Branca RM, Orre LM, Huss M, Fredlund E, Beraki E, Garred Ø, Boekel J, Sauer T, Zhao W, Nord S, Höglander EK, Jans DC, Brismar H, Haukaas TH, Bathen TF, Schlichting E, Naume B; Consortia Oslo Breast Cancer Research Consortium (OSBREAC), Luders T, Borgen E, Kristensen VN, Russnes HG, Lingjærde OC, Mills GB, Sahlberg KK, Børresen-Dale AL, Lehtiö J.

Nat Commun. 2019 Apr 8;10(1):1600. doi: 10.1038/s41467-019-09018-y.

6.

The immune microenvironment in non-small cell lung cancer is predictive of prognosis after surgery.

Öjlert ÅK, Halvorsen AR, Nebdal D, Lund-Iversen M, Solberg S, Brustugun OT, Lingjaerde OC, Helland Å.

Mol Oncol. 2019 May;13(5):1166-1179. doi: 10.1002/1878-0261.12475. Epub 2019 Apr 10.

7.

A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy.

Steen CB, Leich E, Myklebust JH, Lockmer S, Wise JF, Wahlin BE, Østenstad B, Liestøl K, Kimby E, Rosenwald A, Smeland EB, Holte H, Lingjærde OC, Brodtkorb M.

Haematologica. 2019 Oct;104(10):e460-e464. doi: 10.3324/haematol.2018.209080. Epub 2019 Mar 7. No abstract available.

8.

Author Correction: Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors.

Cheng J, Demeulemeester J, Wedge DC, Vollan HKM, Pitt JJ, Russnes HG, Pandey BP, Nilsen G, Nord S, Bignell GR, White KP, Børresen-Dale AL, Campbell PJ, Kristensen VN, Stratton MR, Lingjærde OC, Moreau Y, Van Loo P.

Nat Commun. 2019 Jan 28;10(1):525. doi: 10.1038/s41467-019-08512-7.

9.

Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GKJ, Jang SJ, Jones DR, Kim HY, King TA, Krishnamurthy S, Lee HJ, Lee JY, Li Y, McLaren S, Menzies A, Mustonen V, O'Meara S, Pauporté I, Pivot X, Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux I, Van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, Van't Veer L, Tutt A, Knappskog S, Tan BKT, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JWM, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Stratton MR.

Nature. 2019 Feb;566(7742):E1. doi: 10.1038/s41586-019-0883-2.

PMID:
30659290
10.

Convergence of risk prediction models in follicular lymphoma.

Silva A, Bassim S, Sarkozy C, Mottok A, Lackraj T, Jurinovic V, Brodtkorb M, Lingjaerde OC, Sehn LH, Gascoyne RD, Weigert O, Steidl C, Kridel R.

Haematologica. 2019 Jun;104(6):e252-e255. doi: 10.3324/haematol.2018.209031. Epub 2019 Jan 3. No abstract available.

11.

Author Correction: Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors.

Cheng J, Demeulemeester J, Wedge DC, Vollan HKM, Pitt JJ, Russnes HG, Pandey BP, Nilsen G, Nord S, Bignell GR, White KP, Børresen-Dale AL, Campbell PJ, Kristensen VN, Stratton MR, Lingjærde OC, Moreau Y, Van Loo P.

Nat Commun. 2018 Dec 17;9(1):5397. doi: 10.1038/s41467-018-07842-2.

12.

Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations.

Höglander EK, Nord S, Wedge DC, Lingjærde OC, Silwal-Pandit L, Gythfeldt HV, Vollan HKM, Fleischer T, Krohn M, Schlitchting E, Borgen E, Garred Ø, Holmen MM, Wist E, Naume B, Van Loo P, Børresen-Dale AL, Engebraaten O, Kristensen V.

Genome Med. 2018 Nov 29;10(1):92. doi: 10.1186/s13073-018-0601-y.

13.

Neutral tumor evolution?

Tarabichi M, Martincorena I, Gerstung M, Leroi AM, Markowetz F; PCAWG Evolution and Heterogeneity Working Group, Spellman PT, Morris QD, Lingjærde OC, Wedge DC, Van Loo P.

Nat Genet. 2018 Dec;50(12):1630-1633. doi: 10.1038/s41588-018-0258-x. No abstract available.

14.

Intratumor heterogeneity defines treatment-resistant HER2+ breast tumors.

Rye IH, Trinh A, Saetersdal AB, Nebdal D, Lingjaerde OC, Almendro V, Polyak K, Børresen-Dale AL, Helland Å, Markowetz F, Russnes HG.

Mol Oncol. 2018 Nov;12(11):1838-1855. doi: 10.1002/1878-0261.12375. Epub 2018 Sep 21.

15.

The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy.

Holte H, Beiske K, Boyle M, Trøen G, Blaker YN, Myklebust J, Kvaløy S, Rosenwald A, Lingjaerde OC, Rimsza LM, Smeland EB, Scott DW, Kolstad A.

Br J Haematol. 2018 Oct;183(2):225-234. doi: 10.1111/bjh.15518. Epub 2018 Aug 6.

16.

Reply to Park et al.: Human ectoparasite transmission of plague during the Second Pandemic is still plausible.

Dean KR, Krauer F, Walløe L, Lingjærde OC, Bramanti B, Stenseth NC, Schmid BV.

Proc Natl Acad Sci U S A. 2018 Aug 21;115(34):E7894-E7895. doi: 10.1073/pnas.1810221115. Epub 2018 Aug 3. No abstract available.

17.

N-glycan signatures identified in tumor interstitial fluid and serum of breast cancer patients: association with tumor biology and clinical outcome.

Terkelsen T, Haakensen VD, Saldova R, Gromov P, Hansen MK, Stöckmann H, Lingjaerde OC, Børresen-Dale AL, Papaleo E, Helland Å, Rudd PM, Gromova I.

Mol Oncol. 2018 Jun;12(6):972-990. doi: 10.1002/1878-0261.12312. Epub 2018 May 14.

18.

Artesunate shows potent anti-tumor activity in B-cell lymphoma.

Våtsveen TK, Myhre MR, Steen CB, Wälchli S, Lingjærde OC, Bai B, Dillard P, Theodossiou TA, Holien T, Sundan A, Inderberg EM, Smeland EB, Myklebust JH, Oksvold MP.

J Hematol Oncol. 2018 Feb 20;11(1):23. doi: 10.1186/s13045-018-0561-0.

19.

Human ectoparasites and the spread of plague in Europe during the Second Pandemic.

Dean KR, Krauer F, Walløe L, Lingjærde OC, Bramanti B, Stenseth NC, Schmid BV.

Proc Natl Acad Sci U S A. 2018 Feb 6;115(6):1304-1309. doi: 10.1073/pnas.1715640115. Epub 2018 Jan 16.

20.

Correction to: A systematic comparison of copy number alterations in four types of female cancer.

Kaveh F, Baumbusch LO, Nebdal D, Børresen-Dale AL, Lingjærde OC, Edvardsen H, Kristensen VN, Solvang HK.

BMC Cancer. 2018 Jan 16;18(1):80. doi: 10.1186/s12885-017-3766-7.

21.

T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling.

Josefsson SE, Huse K, Kolstad A, Beiske K, Pende D, Steen CB, Inderberg EM, Lingjærde OC, Østenstad B, Smeland EB, Levy R, Irish JM, Myklebust JH.

Clin Cancer Res. 2018 Feb 15;24(4):870-881. doi: 10.1158/1078-0432.CCR-17-2337. Epub 2017 Dec 7.

22.

Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors.

Cheng J, Demeulemeester J, Wedge DC, Vollan HKM, Pitt JJ, Russnes HG, Pandey BP, Nilsen G, Nord S, Bignell GR, White KP, Børresen-Dale AL, Campbell PJ, Kristensen VN, Stratton MR, Lingjærde OC, Moreau Y, Van Loo P.

Nat Commun. 2017 Oct 31;8(1):1221. doi: 10.1038/s41467-017-01355-0. Erratum in: Nat Commun. 2018 Dec 17;9(1):5397. Nat Commun. 2019 Jan 28;10(1):525.

23.

Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate.

Ree AH, Russnes HG, Heinrich D, Dueland S, Boye K, Nygaard V, Silwal-Pandit L, Østrup O, Hovig E, Nygaard V, Rødland EA, Nakken S, Øien JT, Johansen C, Bergheim IR, Skarpeteig V, Sathermugathevan M, Sauer T, Lund-Iversen M, Beiske K, Nasser S, Julsrud L, Reisse CH, Ruud EA, Flørenes VA, Hagene KT, Aas E, Lurås H, Johnsen-Soriano S, Geitvik GA, Lingjærde OC, Børresen-Dale AL, Mælandsmo GM, Flatmark K.

ESMO Open. 2017 May 2;2(2):e000158. doi: 10.1136/esmoopen-2017-000158. eCollection 2017.

24.

Breast Cancer Molecular Stratification: From Intrinsic Subtypes to Integrative Clusters.

Russnes HG, Lingjærde OC, Børresen-Dale AL, Caldas C.

Am J Pathol. 2017 Oct;187(10):2152-2162. doi: 10.1016/j.ajpath.2017.04.022. Epub 2017 Jul 19. Review.

PMID:
28733194
25.

chimeraviz: a tool for visualizing chimeric RNA.

Lågstad S, Zhao S, Hoff AM, Johannessen B, Lingjærde OC, Skotheim RI.

Bioinformatics. 2017 Sep 15;33(18):2954-2956. doi: 10.1093/bioinformatics/btx329.

26.

The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer.

Silwal-Pandit L, Nord S, von der Lippe Gythfeldt H, Møller EK, Fleischer T, Rødland E, Krohn M, Borgen E, Garred Ø, Olsen T, Vu P, Skjerven H, Fangberget A, Holmen MM, Schlitchting E, Wille E, Nordberg Stokke M, Moen Vollan HK, Kristensen V, Langerød A, Lundgren S, Wist E, Naume B, Lingjærde OC, Børresen-Dale AL, Engebraaten O.

Clin Cancer Res. 2017 Aug 15;23(16):4662-4670. doi: 10.1158/1078-0432.CCR-17-0160. Epub 2017 May 9.

27.

Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome.

Aure MR, Vitelli V, Jernström S, Kumar S, Krohn M, Due EU, Haukaas TH, Leivonen SK, Vollan HK, Lüders T, Rødland E, Vaske CJ, Zhao W, Møller EK, Nord S, Giskeødegård GF, Bathen TF, Caldas C, Tramm T, Alsner J, Overgaard J, Geisler J, Bukholm IR, Naume B, Schlichting E, Sauer T, Mills GB, Kåresen R, Mælandsmo GM, Lingjærde OC, Frigessi A, Kristensen VN, Børresen-Dale AL, Sahlberg KK; OSBREAC.

Breast Cancer Res. 2017 Mar 29;19(1):44. doi: 10.1186/s13058-017-0812-y.

28.

Patterns of constitutively phosphorylated kinases in B cells are associated with disease severity in common variable immunodeficiency.

Taraldsrud E, Aukrust P, Jørgensen S, Lingjærde OC, Olweus J, Myklebust JH, Fevang B.

Clin Immunol. 2017 Feb;175:69-74. doi: 10.1016/j.clim.2016.11.014. Epub 2016 Dec 3.

PMID:
27919819
29.

A systematic comparison of copy number alterations in four types of female cancer.

Kaveh F, Baumbusch LO, Nebdal D, Børresen-Dale AL, Lingjærde OC, Edvardsen H, Kristensen VN, Solvang HK.

BMC Cancer. 2016 Nov 22;16(1):913. doi: 10.1186/s12885-016-2899-4. Erratum in: BMC Cancer. 2018 Jan 16;18(1):80.

30.

The Genomic Landscape of Pancreatic and Periampullary Adenocarcinoma.

Sandhu V, Wedge DC, Bowitz Lothe IM, Labori KJ, Dentro SC, Buanes T, Skrede ML, Dalsgaard AM, Munthe E, Myklebost O, Lingjærde OC, Børresen-Dale AL, Ikdahl T, Van Loo P, Nord S, Kure EH.

Cancer Res. 2016 Sep 1;76(17):5092-102. doi: 10.1158/0008-5472.CAN-16-0658. Epub 2016 Aug 3.

31.

Intra-patient Inter-metastatic Genetic Heterogeneity in Colorectal Cancer as a Key Determinant of Survival after Curative Liver Resection.

Sveen A, Løes IM, Alagaratnam S, Nilsen G, Høland M, Lingjærde OC, Sorbye H, Berg KC, Horn A, Angelsen JH, Knappskog S, Lønning PE, Lothe RA.

PLoS Genet. 2016 Jul 29;12(7):e1006225. doi: 10.1371/journal.pgen.1006225. eCollection 2016 Jul.

32.

Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes.

Haukaas TH, Euceda LR, Giskeødegård GF, Lamichhane S, Krohn M, Jernström S, Aure MR, Lingjærde OC, Schlichting E, Garred Ø, Due EU, Mills GB, Sahlberg KK, Børresen-Dale AL, Bathen TF; Oslo Breast Cancer Consortium (OSBREAC).

Cancer Metab. 2016 Jun 27;4:12. doi: 10.1186/s40170-016-0152-x. eCollection 2016.

33.

The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era.

Blaker YN, Spetalen S, Brodtkorb M, Lingjaerde OC, Beiske K, Østenstad B, Sander B, Wahlin BE, Melen CM, Myklebust JH, Holte H, Delabie J, Smeland EB.

Br J Haematol. 2016 Oct;175(1):102-14. doi: 10.1111/bjh.14201. Epub 2016 Jun 24.

PMID:
27341313
34.

Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GK, Jang SJ, Jones DR, Kim HY, King TA, Krishnamurthy S, Lee HJ, Lee JY, Li Y, McLaren S, Menzies A, Mustonen V, O'Meara S, Pauporté I, Pivot X, Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux I, Van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, van't Veer L, Tutt A, Knappskog S, Tan BK, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JW, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Stratton MR.

Nature. 2016 Jun 2;534(7605):47-54. doi: 10.1038/nature17676. Epub 2016 May 2. Erratum in: Nature. 2019 Feb;566(7742):E1.

35.

Differential expression of miRNAs in pancreatobiliary type of periampullary adenocarcinoma and its associated stroma.

Sandhu V, Bowitz Lothe IM, Labori KJ, Skrede ML, Hamfjord J, Dalsgaard AM, Buanes T, Dube G, Kale MM, Sawant S, Kulkarni-Kale U, Børresen-Dale AL, Lingjærde OC, Kure EH.

Mol Oncol. 2016 Feb;10(2):303-16. doi: 10.1016/j.molonc.2015.10.011. Epub 2015 Nov 3.

36.

Serum N-Glycome Characterization in Patients with Resectable Periampullary Adenocarcinoma.

Hamfjord J, Saldova R, Stöckmann H, Sandhu V, Bowitz Lothe IM, Buanes T, Lingjærde OC, Labori KJ, Rudd PM, Kure EH.

J Proteome Res. 2015 Dec 4;14(12):5144-56. doi: 10.1021/acs.jproteome.5b00395. Epub 2015 Nov 17.

PMID:
26515733
37.

Canine Mammary Tumours Are Affected by Frequent Copy Number Aberrations, including Amplification of MYC and Loss of PTEN.

Borge KS, Nord S, Van Loo P, Lingjærde OC, Gunnes G, Alnæs GI, Solvang HK, Lüders T, Kristensen VN, Børresen-Dale AL, Lingaas F.

PLoS One. 2015 May 8;10(5):e0126371. doi: 10.1371/journal.pone.0126371. eCollection 2015.

38.

Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF.

Tinholt M, Vollan HK, Sahlberg KK, Jernström S, Kaveh F, Lingjærde OC, Kåresen R, Sauer T, Kristensen V, Børresen-Dale AL, Sandset PM, Iversen N.

Breast Cancer Res. 2015 Mar 26;17:44. doi: 10.1186/s13058-015-0548-5.

39.

Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer.

Aure MR, Jernström S, Krohn M, Vollan HK, Due EU, Rødland E, Kåresen R; Oslo Breast Cancer Research Consortium (OSBREAC), Ram P, Lu Y, Mills GB, Sahlberg KK, Børresen-Dale AL, Lingjærde OC, Kristensen VN.

Genome Med. 2015 Feb 2;7(1):21. doi: 10.1186/s13073-015-0135-5. eCollection 2015.

40.

Glycan-related gene expression signatures in breast cancer subtypes; relation to survival.

Potapenko IO, Lüders T, Russnes HG, Helland Å, Sørlie T, Kristensen VN, Nord S, Lingjærde OC, Børresen-Dale AL, Haakensen VD.

Mol Oncol. 2015 Apr;9(4):861-76. doi: 10.1016/j.molonc.2014.12.013. Epub 2015 Jan 14.

41.

Molecular signatures of mRNAs and miRNAs as prognostic biomarkers in pancreatobiliary and intestinal types of periampullary adenocarcinomas.

Sandhu V, Bowitz Lothe IM, Labori KJ, Lingjærde OC, Buanes T, Dalsgaard AM, Skrede ML, Hamfjord J, Haaland T, Eide TJ, Børresen-Dale AL, Ikdahl T, Kure EH.

Mol Oncol. 2015 Apr;9(4):758-71. doi: 10.1016/j.molonc.2014.12.002. Epub 2014 Dec 19.

42.

The multitude of molecular analyses in cancer: the opening of Pandora’s box.

Russnes HG, Lønning PE, Børresen-Dale AL, Lingjærde OC.

Genome Biol. 2014;15(9):447.

43.

A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer.

Vollan HK, Rueda OM, Chin SF, Curtis C, Turashvili G, Shah S, Lingjærde OC, Yuan Y, Ng CK, Dunning MJ, Dicks E, Provenzano E, Sammut S, McKinney S, Ellis IO, Pinder S, Purushotham A, Murphy LC, Kristensen VN; METABRIC Group, Brenton JD, Pharoah PD, Børresen-Dale AL, Aparicio S, Caldas C.

Mol Oncol. 2015 Jan;9(1):115-27. doi: 10.1016/j.molonc.2014.07.019. Epub 2014 Aug 8.

44.

Principles and methods of integrative genomic analyses in cancer.

Kristensen VN, Lingjærde OC, Russnes HG, Vollan HK, Frigessi A, Børresen-Dale AL.

Nat Rev Cancer. 2014 May;14(5):299-313. doi: 10.1038/nrc3721. Review.

PMID:
24759209
45.

Systematic assessment of prognostic gene signatures for breast cancer shows distinct influence of time and ER status.

Zhao X, Rødland EA, Sørlie T, Vollan HK, Russnes HG, Kristensen VN, Lingjærde OC, Børresen-Dale AL.

BMC Cancer. 2014 Mar 19;14:211. doi: 10.1186/1471-2407-14-211.

46.

Whole-genome integrative analysis reveals expression signatures predicting transformation in follicular lymphoma.

Brodtkorb M, Lingjærde OC, Huse K, Trøen G, Hystad M, Hilden VI, Myklebust JH, Leich E, Rosenwald A, Delabie J, Holte H, Smeland EB.

Blood. 2014 Feb 13;123(7):1051-4. doi: 10.1182/blood-2013-07-512392. Epub 2013 Dec 19.

PMID:
24357726
47.

Individual and combined effects of DNA methylation and copy number alterations on miRNA expression in breast tumors.

Aure MR, Leivonen SK, Fleischer T, Zhu Q, Overgaard J, Alsner J, Tramm T, Louhimo R, Alnæs GI, Perälä M, Busato F, Touleimat N, Tost J, Børresen-Dale AL, Hautaniemi S, Troyanskaya OG, Lingjærde OC, Sahlberg KK, Kristensen VN.

Genome Biol. 2013 Nov 20;14(11):R126. doi: 10.1186/gb-2013-14-11-r126.

48.

Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment.

Kjersem JB, Ikdahl T, Lingjaerde OC, Guren T, Tveit KM, Kure EH.

Mol Oncol. 2014 Feb;8(1):59-67. doi: 10.1016/j.molonc.2013.09.001. Epub 2013 Sep 21.

49.

Identifying clusters in genomics data by recursive partitioning.

Nilsen G, Borgan O, Liestøl K, Lingjærde OC.

Stat Appl Genet Mol Biol. 2013 Oct 1;12(5):637-52. doi: 10.1515/sagmb-2013-0016.

PMID:
23942354
50.

Influence of DNA copy number and mRNA levels on the expression of breast cancer related proteins.

Myhre S, Lingjærde OC, Hennessy BT, Aure MR, Carey MS, Alsner J, Tramm T, Overgaard J, Mills GB, Børresen-Dale AL, Sørlie T.

Mol Oncol. 2013 Jun;7(3):704-18. doi: 10.1016/j.molonc.2013.02.018. Epub 2013 Mar 19.

Supplemental Content

Loading ...
Support Center